Company news
Atossa Therapeutics, Inc. news in 2021
Atossa Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.
Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden
December 21, 2021
Atossa Therapeutics Completes Pre-IND Meeting with U.S. Food & Drug Administration
December 5, 2021
Atossa Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update
November 14, 2021
Atossa Therapeutics Begins Enrollment in Clinical Study of AT-H201 in Australia
September 29, 2021
Atossa Therapeutics Adjourns Special Stockholder Meeting to October 7, 2021 to Allow Additional Time to Vote
September 6, 2021
Atossa Therapeutics Receives Approval from the Swedish Ethics Review Authority to Initiate a Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density in Sweden
September 1, 2021
Atossa Therapeutics Announces Second Quarter 2021 Financial Results - Provides Corporate Update and Information about Upcoming Stockholder Meeting
August 12, 2021
Atossa Therapeutics Receives Regulatory Approval To Open Clinical Study of AT-H201 in Australia
July 6, 2021
Atossa Therapeutics Receives Approval from Swedish Regulators to Initiate Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density
June 10, 2021
Atossa Therapeutics Announces Final Data from Phase 2 Endoxifen Breast Cancer Study Primary Endpoint Met: 65.1% Reduction in Biomarker Ki-67; Secondary Endpoint Met: Endoxifen Safe and Well Tolerated
June 8, 2021
Atossa Therapeutics to Release Final Data from Phase 2 Study of Endoxifen Administered to Breast Cancer Patients Prior to Surgery at a Webinar at 8 am Pacific Time on June 9, 2021
June 6, 2021
Atossa Therapeutics Announces First Quarter 2021 Financial Results and Provides Corporate Update
May 13, 2021
Atossa Therapeutics Urges Shareholders to Vote on Proposals Ahead of its Annual Stockholder Meeting May 14, 2021 at 1: 00 PM Pacific Time
May 10, 2021
Atossa Therapeutics Announces Ovarian Cancer Patient has Begun Treatment with Oral Endoxifen under FDA’s Expanded Access Pathway
April 7, 2021
Atossa Therapeutics Announces Year End 2020 Financial Results and Provides Corporate Update
March 30, 2021
Atossa Therapeutics Announces Pricing of $50.0 Million Registered Direct Offering Priced At-The-Market
March 21, 2021
Atossa Therapeutics Announces Receipt of FDA Safe to Proceed Letter for Treatment of an Ovarian Cancer Patient with Oral Endoxifen Under Expanded Access Pathway
March 10, 2021
Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19
February 24, 2021
Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Accomplishments and Strategy for 2021
February 9, 2021
Atossa Therapeutics Announces Two-Year Update of FDA-Approved Expanded Access Treatment with Endoxifen
February 2, 2021
Atossa Therapeutics’ Phase 2 Endoxifen Breast Cancer Study Produces Substantially Positive Results Allowing Study to be Halted Early
February 1, 2021
Atossa Therapeutics Announces Pricing of $25.2 Million Registered Direct Offering Priced At-The-Market
January 5, 2021